← Back to Analyst Consensus 
SKYE Buy
Skye Bioscience, Inc.
Current Price —
Implied Upside —
Analysts 10
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Nov 9, 2026 (14 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Sep 30, 2025 | HC Wainwright & Co. | initiate | — → Buy | $20 | 44% |
| Aug 15, 2025 | Evercore ISI Group | initiate | — → Outperform | $10 | 58% |
| Jun 24, 2025 | JMP Securities | reiterate | Market Outperform → Market Outperform | $15 | 53% |
| Mar 21, 2025 | Craig-Hallum | maintain | Buy → Buy | $14 | 54% |
| Mar 21, 2025 | Citizens Capital Markets | reiterate | Market Outperform → Market Outperform | $15 | 49% |
| Feb 28, 2025 | William Blair | initiate | — → Outperform | $0 | 48% |
| Sep 30, 2024 | Scotiabank | initiate | — → Sector Outperform | $20 | 55% |
| Sep 20, 2024 | Piper Sandler | reiterate | Overweight → Overweight | $20 | 54% |
| Sep 20, 2024 | Cantor Fitzgerald | reiterate | Overweight → Overweight | $14 | 50% |
| Sep 10, 2024 | JMP Securities | initiate | — → Market Outperform | $15 | 53% |
| Sep 9, 2024 | Cantor Fitzgerald | reiterate | Overweight → Overweight | $14 | 50% |
| Sep 6, 2024 | Cantor Fitzgerald | reiterate | Overweight → Overweight | $14 | 50% |
| Aug 27, 2024 | Cantor Fitzgerald | reiterate | Overweight → Overweight | $14 | 50% |
| Jul 9, 2024 | Craig-Hallum | initiate | — → Buy | $18 | 54% |
| Jul 1, 2024 | Cantor Fitzgerald | reiterate | Overweight → Overweight | $14 | 50% |
| Jun 18, 2024 | Cantor Fitzgerald | reiterate | Overweight → Overweight | $14 | 50% |
| Jun 17, 2024 | Cantor Fitzgerald | reiterate | Overweight → Overweight | $14 | 50% |
| May 23, 2024 | Cantor Fitzgerald | initiate | — → Overweight | $21 | 50% |
| Apr 12, 2024 | Oppenheimer | initiate | — → Outperform | $25 | 52% |
| Mar 14, 2024 | Piper Sandler | reiterate | Overweight → Overweight | $20 | 54% |
| Feb 5, 2024 | Piper Sandler | initiate | — → Overweight | $12 | 54% |
Price Target Trend
Apr 2, 2026 Oct 26, 2026
EPS Estimates
0q —
+1q —
+1y —
0y —
Cross-Platform Signals
No cross-platform signals in the last 90 days